| Literature DB >> 29943470 |
Qi Shan1, Jingxin Wang1, Jing Wang2, Lisha Ma1, Fenghua Yang2, Yi Yin1, Ren Huang2, Shugui Liu1, Lichun Li1, Guangming Zheng1.
Abstract
The pharmacokinetic (PK) properties of enrofloxacin (ENR) and its metabolite ciprofloxacin (CIP) were investigated in crucian carp following oral administration at different dose levels (5, 10, 20, 40 mg/kg body weight). The disposition kinetics of ENR was found to be linear over the dose range studied. Serum half-lives ranged from 64.56 to 72.68 hr. The in vitro and ex vivo activities of ENR in serum against a pathogenic strain of Aeromonas hydrophila were determined. In vitro and ex vivo bactericidal activity of ENR was concentration dependent. Dosing of 10 mg/kg resulted in an AUC/minimum inhibitory concentration (MIC) ratio of 368.92 hr and a Cmax /MIC ratio of 7.23, respectively, against A. hydrophila 147 (MIC = 0.48 μg/ml), indicating a likely high level of effectiveness in clinical infections caused by A. hydrophila with MIC value ≤ 0.48 μg/ml. Modeling of ex vivo growth inhibition data to the sigmoid Emax equation provided the values of AUC24 hr /MIC required to produce bacteriostasis, bactericidal activity, and elimination of bacteria, these values were 21.70, 53.01, and 125.21 hr, respectively. These findings in conjunction with MIC90 data suggested that ENR at the dose of 7.81 mg/kg predicted a positive clinical outcome and minimize the risk of emergence of resistance.Entities:
Keywords: zzm321990A. hydrophilazzm321990; crucian carp; enrofloxacin; pharmacokinetic/pharmacodynamics model; pharmacokinetics
Mesh:
Substances:
Year: 2018 PMID: 29943470 DOI: 10.1111/jvp.12678
Source DB: PubMed Journal: J Vet Pharmacol Ther ISSN: 0140-7783 Impact factor: 1.786